Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 18/20 | 0.67 |
| ▸ | CTSG | P08311 | 6/20 | 0.52 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318188 | 0.90 | CMA1 (0.71) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL8119222 | 0.89 | CMA1 (0.52) | CMA1CTSGKMT2A | |
| SCHEMBL2312625 | 0.82 | CMA1 (1.00) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL8113055 | 0.80 | CMA1 (0.79) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL8105798 | 0.80 | CMA1 (0.79) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2311834 | 0.80 | CMA1 (0.67) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2309320 | 0.80 | CMA1 (0.67) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2809708 | 0.79 | CMA1 (0.61) | CMA1CTSG | |
| SCHEMBL2310106 | 0.79 | CMA1 (0.63) | CMA1CTSG | |
| SCHEMBL8119208 | 0.79 | CMA1 (0.60) | CMA1CTSGKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CMA1 1/4885CTSG 26/4885SLC12A2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.